open access
The role of visfatin in pathogenesis of gestational diabetes (GDM)
Affiliations- Department of Obstetrics and Women’s Diseases, University of Medical Sciences, Poznan, Poland
open access
Abstract
Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM.
Abstract
Gestational diabetes (GDM) is defined as a glucose intolerance of varying severity with onset or first recognition during pregnancy. Two major metabolic disorders: insulin resistance and β-cells dysfunction, play currently major role in pathogenesis of GDM. Adipose tissue is an organ involved in production of adipokines, which have various influence on metabolism of glucose and lipids. Visfatin is an adipokine mainly produced and secreted by the fat tissue. It exerts an insulin-like effect by binding to the insulin receptor-1 and have hypoglycemic effect. Visfatin appears to be an important factor in the pathophysiology of GDM. The aim of this article is to review the literature concerning the relationship between the adipokine mentioned above and GDM, and to clarify its role in the pathophysiology of GDM.
Keywords
visfatin, NAMPT, gestational diabetes mellitus, GDM, adipocytokines
About this articleTitle
The role of visfatin in pathogenesis of gestational diabetes (GDM)
Journal
Issue
Article type
Review paper
Pages
518-521
Published online
2018-09-28
Page views
7165
Article views/downloads
4862
DOI
Pubmed
Bibliographic record
Ginekol Pol 2018;89(9):518-521.
Keywords
visfatin
NAMPT
gestational diabetes mellitus
GDM
adipocytokines
Authors
Sandra Radzicka
Marek Pietryga
Rafal Iciek
Jacek Brązert
References (35)- McCance D. Gestational Diabetes Mellitus. The Evidence Base for Diabetes Care. 2004: 88–90.
- Petry CJ. Gestational diabetes: risk factors and recent advances in its genetics and treatment. Br J Nutr. 2010; 104(6): 775–787.
- Landon MB, Gabbe SG. Gestational diabetes mellitus. Obstet Gynecol. 2011; 118(6): 1379–1393.
- Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care. 2008; 31(2): 340–346.
- Retnakaran R, Qi Y, Sermer M, et al. Glucose Intolerance in Pregnancy and Future Risk of Pre-Diabetes or Diabetes. Diabetes Care. 2008; 31(10): 2026–2031.
- Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med. 2004; 21(2): 103–113.
- Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11(2): 85–97.
- Harlev A, Wiznitzer A. New insights on glucose pathophysiology in gestational diabetes and insulin resistance. Curr Diab Rep. 2010; 10(3): 242–247.
- Kralisch S, Bluher M, Paschke R, et al. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem. 2007; 7(1): 39–45.
- Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307(5708): 426–430.
- Haider DG, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia. 2006; 49(8): 1909–1914.
- Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem. 2008; 15(18): 1851–1862.
- Chang YH, Chang DM, Lin KC, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011; 27(6): 515–527.
- Mazaki-Tovi S, Romero R, Kusanovic JP, et al. Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight. J Perinat Med. 2009; 37(3): 218–231.
- Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond). 2006; 110(5): 605–609.
- Lewandowski KC, Stojanovic N, Press M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia. 2007; 50(5): 1033–1037.
- Zhaoxia L, Ying Wu, Danqing C. Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus. Diabetes Res Clin Pract. 2012; 96(3): e76–e79.
- Gok DE, Yazici M, Uckaya G, et al. The role of visfatin in the pathogenesis of gestational diabetes mellitus. J Endocrinol Invest. 2011; 34(1): 3–7.
- Chan TF, Chen YL, Lee CH, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig. 2006; 13(5): 364–367.
- Akturk M, Altinova AE, Mert I, et al. Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest. 2008; 31(7): 610–613.
- Rezvan N, Hosseinzadeh-Attar MJ, Masoudkabir F, et al. Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy. Arch Gynecol Obstet. 2012; 285(5): 1257–1262.
- Telejko B, Kuzmicki M, Zonenberg A, et al. Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. Diabetes Res Clin Pract. 2009; 84(1): 68–75.
- Görkem Ü, Küçükler FK, Toğrul C, et al. Are adipokines associated with gestational diabetes mellitus? J Turk Ger Gynecol Assoc. 2016; 17(4): 186–190.
- Kim D, Kang S, Moon N, et al. Central visfatin potentiates glucose-stimulated insulin secretion and β-cell mass without increasing serum visfatin levels in diabetic rats. Cytokine. 2014; 65(2): 159–166.
- Ferreira AF, Rezende JC, Vaikousi E, et al. Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem. 2011; 57(4): 609–613.
- Zhaoxia L, Ying Wu, Danqing C. Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus. Diabetes Res Clin Pract. 2012; 96(3): e76–e79.
- Morgan SA, Bringolf JB, Seidel ER. Visfatin expression is elevated in normal human pregnancy. Peptides. 2008; 29(8): 1382–1389.
- Coskun A, Ozkaya M, Kiran G, et al. Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2010; 23(9): 1014–1018.
- Kaygusuz I, Gumus II, Yılmaz S, et al. Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus. Gynecol Obstet Invest. 2013; 75(3): 203–209.
- Görkem Ü, Küçükler FK, Toğrul C, et al. Are adipokines associated with gestational diabetes mellitus? J Turk Ger Gynecol Assoc. 2016; 17(4): 186–190.
- Park S, Kim MY, Baik SH, et al. Gestational diabetes is associated with high energy and saturated fat intakes and with low plasma visfatin and adiponectin levels independent of prepregnancy BMI. European Journal of Clinical Nutrition. 2013; 67(2): 196–201.
- Feng J, Li HY, Wang XL, et al. Nicotinamide phosphoribosyltransferase enhances beta cell expansion during pregnancy. Eur Rev Med Pharmacol Sci. 2016; Vol. 20 - N.: 4965–4971.
- Szamatowicz J, Kuźmicki M, Telejko B, et al. Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes. Ginekol Pol. 2009; 80(1): 14–18.
- Iciek R, Brazert M, Wender-Ozegowska E, et al. Low placental visfatin expression is related to impaired glycaemic control and fetal macrosmia in pregnancies complicated by type 1 diabetes. J Physiol Pharmacol. 2018; 69(1): 61–66.
- Fasshauer M. Lancet Diabetes Endocrinol. 2014 Jun; 2(6): 488–499.
